Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~1 h
Time for 50 % to be eliminated
Steady State
~4 h
≈ 4.3 half-lives
Accumulation
×1.00
Cmax at steady state ÷ Cmax first dose
Gone After
~7 h
after last dose
Source: Ugwu et al., Biopharm Drug Dispos 1997 (SC beta-phase 0.8–1.7 h). Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Melanotan I: ~1 h.
A human pharmacokinetic study reported a terminal half-life range of approximately 0.8 to 1.7 hours after subcutaneous exposure; the calculator uses one hour as a representative scalar.
One hour is a modeling simplification inside the published range. It is not a universal constant and must not be transferred to the Scenesse implant or used as scheduling guidance.
Ugwu et al., Biopharmaceutics & Drug Disposition 1997: human terminal half-life range 0.8 to 1.7 hours.
Melanotan I, abbreviated MT-1 or MT-I, is the historical research name for afamelanotide. It is a synthetic tridecapeptide derived from alpha-melanocyte-stimulating hormone research, with amino-acid substitutions designed to alter melanocortin activity and peptide behavior. This product contains 10 mg of lyophilized Melanotan I in a sealed research vial for controlled laboratory work.
Afamelanotide and Melanotan I refer to the same peptide identity in the cited scientific and regulatory sources; they should not be presented as separate compounds. The vial remains a research material rather than a medicine, implant, cosmetic, tanning product, or preparation intended for administration. The 10 mg label identifies the nominal vial format and is not a recommended human dose.
For research use only. Not for human or veterinary use, tanning, diagnosis, treatment, prevention, cosmetic use, or consumption. The presence of afamelanotide in an approved implant does not make this research vial approved, interchangeable, or clinically validated.